Jaguar Health’s Crofelemer Gets Another Compassionate-Use Win in a Tiny but Critical Rare Disease Market

Jaguar Health is expanding the real‑world use of crofelemer, with another infant in the European Union set to receive the drug through compassionate use for intestinal failure caused by microvillus inclusion disease (MVID).

 What happened

Jaguar Health, Inc. (NASDAQ: JAGX) said its Napo Pharmaceuticals unit will provide crofelemer powder for oral solution to an EU infant patient under a compassionate‑use pathway. The child is being treated for intestinal failure due to MVID, an ultrarare genetic disorder that severely disrupts nutrient and fluid absorption. Jaguar said the request follows growing awareness of crofelemer after recent pediatric GI data and expanded access progress in rare intestinal failure.

 Why crofelemer matters

Crofelemer is a botanical oral therapy derived from the red bark sap of the Croton lechleri tree, and Jaguar is developing it for rare pediatric intestinal failure conditions. In ongoing studies and expanded access cases, crofelemer has been linked to reductions in parenteral support needs, including one MVID patient who saw up to a 48% reduction over more than 12 months of use. That matters because children with MVID often depend on long‑term parenteral nutrition and intravenous fluids just to maintain growth and hydration.

The practical takeaway is simple: even a modest reduction in IV support can be meaningful for families and clinicians managing this disease. Jaguar’s update also points to favorable tolerability, with no major clinical or laboratory safety concerns reported in the cases cited. For a condition with no approved cure, that kind of access and early signal can carry real development value.

 Development path and investor angle

Jaguar says it remains focused on its intestinal failure program for oral crofelemer and continues to discuss possible non‑dilutive partnerships to help fund development. The company is also pursuing a regulatory path that could include Breakthrough Therapy Designation and a future FDA filing for MVID. It has already completed enrollment in its blinded pediatric MVID trial, and future data from that study, along with compassionate‑use cases, are expected to support the development strategy.

For investors, the story is less about a huge market and more about proof of concept in a severe orphan disease with no approved treatment. If Jaguar can keep producing favorable pediatric data and translate those cases into regulatory momentum, crofelemer could become a credible rare‑disease asset rather than just a niche gastrointestinal product. The main risks remain execution, funding, and whether the clinical signal is strong enough to support eventual approval.